Objectives: A consensus exists among clinicians that imipenem/cilastatin is the most epileptogenic carbapenem, despite inconsistencies in the literature.
Introduction
Carbapenem antibiotics possess a broad antimicrobial spectrum and are commonly used in complicated and serious bacterial infections. Their use has become increasingly important over time given the dramatic rise in antibiotic resistance, particularly among hospitalized patients, 1 as carbapenems have retained activity against several multiply resistant Gram-negative pathogens. Structurally related to the penicillin family, carbapenems are well tolerated by most patients, but an important side effect of their use is CNS toxicity. 2 In early clinical trials, the use of imipenem was associated with the development of seizures 2, 3 and this adverse effect remains a concern with carbapenem use, particularly at high doses. 4 A general consensus appears to exist among clinicians that imipenem is the most epileptogenic among carbapenems, 4, 5 despite inconsistencies in the literature to support this belief. 4,6 -8 Bacterial meningitis guidelines published by the Infectious Diseases Society of America recommend meropenem over imipenem due to decreased risk of seizure with meropenem. 8 Recent literature reviews have arrived at conflicting conclusions regarding whether there is a difference in the seizure potential between these two carbapenems. 4, 6 In fact, according to FDA-approved labelling the frequency of seizures for imipenem and meropenem is 0.4% 9 and 0.7% 10 respectively. The labelling for ertapenem, a recently FDA-approved carbapenem with a narrower antibiotic spectrum, notes a seizure frequency of 0.5%. 11 Seizures are noted in the prescribing information for doripenem, the newest member of the carbapenems; however, a frequency is not reported. 12 To summarize the evidence on the risk of seizures and comparative epileptogenicity of imipenem, meropenem, ertapenem and doripenem we conducted a meta-analysis of randomized studies that used these agents. The objective was to estimate the risk of seizures associated with each carbapenem relative to non-carbapenem antibiotics and, where possible, directly compare seizure risk across carbapenems.
Methods

Literature review
A search of PubMed and EMBASE was conducted from January 1966 to November 2013 to identify literature for inclusion. The search was limited to randomized controlled trials and English language studies. The search terms used for identification of studies were 'carbapenem' OR 'imipenem' OR 'meropenem' OR 'ertapenem' OR 'doripenem'. References of studies identified in the initial search were reviewed and carbapenem manufacturers were contacted for unpublished data. Studies were reviewed for inclusion by two investigators and included for data extraction if a parenteral carbapenem was compared with a different carbapenem or a non-carbapenem antibiotic. Studies were excluded for lack of active comparison or randomization, failure to mention adverse events, pertinent missing data, including previously published data, or including more than one carbapenem in the same arm of the study. Single-dose studies were also excluded because single dosing is not consistent with how carbapenems are primarily used in clinical practice.
Data extraction
Two investigators independently extracted data from each of the studies identified for inclusion and the following were recorded: study design and quality (e.g. single versus multicentre, allocation generation, allocation concealment, blinding), sponsorship, number of patients included in safety analysis and whether that reflected the intent-to-treat population, study population (e.g. adults, children), comorbidities (e.g. dialysis, history of seizures), indication for antibiotic therapy and dose of carbapenem and noncarbapenem comparator antibiotics. Within each of the treatment arms, the total number of seizures reported was determined, as well as the number of seizures assessed to be probably or definitely drug-related as assessed by the authors. If the authors considered a reaction drug-related but failed to specify their level of conviction, it was assumed to be at least probably related to the study drug. Studies failing to mention adverse effects were excluded from the analysis. The authors of studies for which CNS effects were mentioned but not further specified were contacted to determine the nature of the effects. Studies that reported zero adverse effects or reported adverse effects without specifically stating the absence of seizures, were assumed to have a 0% frequency of seizures.
Statistical analysis
To assess the epileptogenicity of carbapenems and comparator antibiotics, we calculated both the risk difference (RD) effect estimate and the pooled OR between carbapenem arms and comparators. The RD is an estimate of the absolute risk of events between the two arms and allows for inclusion of all studies meeting inclusion criteria regardless of whether or not an event occurred. All studies meeting the inclusion criteria were used to estimate the RD between the carbapenem arms and the comparator arms. The 95% CI of the RD was calculated and heterogeneity across studies was assessed using the Q statistic. 13 Second, studies in which there was at least one seizure in the carbapenem or comparator arm were further combined to calculate pooled ORs. Meta-analyses were performed separately for each carbapenem compared with non-carbapenem comparator antibiotics. Additionally, pooled ORs were calculated for studies that compared carbapenems head to head. The pooled OR results were graphically displayed in forest plots, where the size of the square was directly proportional to the hypergeometric variance of the event count in the intervention group and thus the weight of the study in the analysis. For studies where there were no events in one of the treatment arms, 0.5 was added to each cell of the 2×2 table when calculating the OR. The Peto method was used to calculate a summary OR for each of the comparisons, given that the rate of events being compared was relatively low and there were balanced sample sizes within studies.
14 In addition, we calculated pooled ORs using the Mantel -Haenszel method to determine whether there were differences based on the method used to calculate the summary estimate. Heterogeneity across studies was tested with the Q statistic 13 and the I 2 index to assess for significant differences in the ORs and 95% CI between the included studies. Where significant heterogeneity was noted, a random effects model was used to calculate summary ORs. We conducted several sensitivity analyses in subgroups of studies to evaluate the effects of factors that may contribute to seizure risk. Specifically, we analysed studies separately based on whether they included or excluded patients on dialysis and whether they included or excluded patients with a history of seizures. We also conducted sensitivity analyses using measures of study quality. Publication bias was evaluated using Begg's funnel plots, and sources of heterogeneity were examined by comparing study characteristics. All analyses were performed with Stata v10.1 (Stata Corp., College Station, TX, USA).
Results
We identified 382 studies using the defined search criteria and screened for inclusion; 187 studies were excluded, as described in Figure 1 (for details of excluded studies see Table S1 , available as Supplementary data at JAC Online). There were 21 headto-head studies comparing imipenem with meropenem, 15 -35 2 studies each comparing imipenem with doripenem 36, 37 and imipenem with biapenem 38, 39 and 1 study each comparing meropenem with doripenem 40 and meropenem with panipenem; 41 these were analysed separately (below). Nakagawa et al. 41 included three arms (meropenem, panipenem and cefepime) and thus was included in the head-to-head and non-carbapenem comparator analyses. The meta-analysis of carbapenems versus noncarbapenem comparators therefore included a total of 169 studies, which were used in the RD analysis (Table S2, available as Supplementary data at JAC Online). Of the 169 studies, imipenem, meropenem, ertapenem and doripenem were used in 107 (63%), 41 (24%), 19 (11%) and 2 (1%) studies, respectively (Tables 1 and 2 ). Forty-three of 169 studies reported at least one seizure and these studies were subsequently used to calculate a pooled OR for risk of seizure among patients receiving carbapenem versus non-carbapenem antibiotics. 42 -84 Of the 43 studies, imipenem, meropenem, ertapenem and doripenem were used in 28 (65%), 9 (21%), 4 (9%) and 2 (5%), respectively ( Table 3) .
The RD analysis (n ¼ 169 studies) demonstrated an increased risk of seizures with carbapenems; among patients exposed to carbapenems there were an additional 2 patients with seizures per 1000 persons (95% CI 0.001, 0.004) compared with patients in the non-carbapenem group. Receipt of imipenem was responsible for this difference as the RD for imipenem was 0.004 (95% CI 0.002, 0.007), whereas meropenem, ertapenem and doripenem were not associated with increased seizure risk ( Table 2 ). In addition, the estimated risk of seizure was numerically higher in those receiving higher doses of imipenem, as the pooled RDs for ≤2 g/day and .2 g/day were 0.003 (95% CI 0.0005, 0.006) and 0.008 (95% CI 0.004, 0.013), respectively. Despite the fact that imipenem was associated with an increased risk of seizures versus Systematic review non-carbapenem comparators and meropenem was not, when the two drugs were compared by summarizing risk from head-to-head studies there was no difference seen in RD ( Table 2) .
The findings of the pooled OR analysis were similar to those of the RD analysis. The risk of seizures in the combined carbapenem arms was significantly higher than in non-carbapenem comparator arms (OR 1.87, 95% CI 1.35, 2.59; Figure 2 ). Importantly, there was significant heterogeneity when combining all of the carbapenem studies for a single effect estimate; however, there was no statistically significant heterogeneity for analyses done by specific carbapenems. In the analysis of the 28 studies comparing imipenem alone with non-carbapenem antibiotics, 42 79, 81 respectively. Pooled ORs of each carbapenem versus non-carbapenem comparison were also estimated using the Mantel-Haenszel method, and were similar to the ORs in the primary analysis using the Peto method (data not shown).
Separate sensitivity analyses were used to examine the impact of study design and population (Table 4) . With the exception of single-blind studies, imipenem remained significantly associated with increased seizure risk while meropenem was not associated with seizure risk. Similarly, study population characteristics such as dialysis, seizure history, limiting the comparators to b-lactams and excluding meningitis studies resulted in findings similar to those of the overall analysis. It is worth noting that when the three meningitis studies were excluded, the meropenem point estimate increased by .2-fold (pooled OR 2.24, 95% CI 0.75, 6.67), albeit remaining statistically non-significant.
To assess the difference in epileptogenicity between imipenem and meropenem more directly, the 21 studies in which they were compared head to head were analysed. 15 -35 There was no difference in the RD for risk of seizure with receipt of imipenem compared with meropenem (0.001, 95% CI 20.003, 0.006; Table 2 ). Of these 21 studies, 7 reported at least one seizure and were pooled to calculate the summary OR for the risk of seizures comparing the medications head to head. 17, 20, 21, 23, 26, 29, 33 The point estimate demonstrated a higher frequency of seizures in the imipenem-treated patients (OR 1.48, 95% CI 0.54, 4.04; Figure 3) ; however, the difference was not statistically significant. In sensitivity analyses of the head-to-head studies that either included or excluded patients on dialysis and included or excluded those with a history of seizure, there was no significant difference in seizure risk between imipenem and meropenem (data not shown).
There were two studies in which doripenem was compared with imipenem; 36,37 the OR for risk of seizures with imipenem compared with doripenem was 3.00 (95% CI 0.998, 9.01), based on one study with seizures. 36 There was no difference in Multiple studies included patients with more than one site of infection. 
Continued
Systematic review the RD analysis. In the two imipenem versus biapenem studies 38, 39 and the one study each of doripenem versus meropenem 40 and meropenem versus panipenem, 41 there was no difference in seizures based on the RD analysis; pooled ORs were not calculated due to the absence of seizures in any arm.
Discussion
This meta-analysis demonstrated that, although the overall frequency of seizures in patients receiving carbapenems is low, when compared with non-carbapenems there is a significantly increased risk of seizures associated with carbapenem usage. Within the meta-analysis, the increased risk was predominantly due to increased risk in the imipenem studies, as the risk of seizure among recipients of meropenem was similar to that among recipients of non-carbapenem antibiotics. There were also no differences in epileptogenicity between ertapenem or doripenem compared with non-carbapenem antibiotics; however, these analyses are limited by the small number of studies that included these carbapenems. Interestingly, the risk of seizure with imipenem was not increased when comparing studies that included patients with a history of seizure (n¼ 21) with those that excluded patients with a seizure history (n ¼ 7), although the latter group may have been too small to detect a significant difference. However, the seizure risk was numerically higher in studies that included patients requiring dialysis. Also, in both the RD and pooled OR analyses, there was a trend towards increased risk of seizure as the total daily imipenem dose exceeded 2 g. Seizure risk with meropenem did not appear to be associated with a prior history of seizures or renal failure requiring dialysis, although most of the meropenem studies excluded patients with a seizure history.
It is worth noting the impact on the results when the three meningitis studies were excluded, 57, 64, 85 since seizures are a known complication of meningitis. 86, 87 Two of these studies were conducted in young children. 57, 64 Odio et al. 64 reported high seizure rates in both arms (12% among meropenem recipients and 17% among cefotaxime recipients), although the investigators considered none of the events to be drug-related and classified them as complications of the underlying infection.
Similarly, Klugman and Dagan 57 reported seizures in 6% and 3% of patients receiving meropenem and cefotaxime, respectively; none of the seizures was classified as drug-related. Schmutzhard et al. 85 described no seizures among adults with bacterial meningitis treated with meropenem or a thirdgeneration cephalosporin. In the sensitivity analysis excluding these three studies the meropenem OR increased from 1.04 to 2.24, although it remained statistically non-significant.
The 21 studies in which imipenem and meropenem were compared head to head revealed no difference in seizure risk in the RD analysis. 15 -35,88 Of these 21 studies, the 7 with at least one episode of seizure 17, 20, 21, 23, 26, 29, 33 similarly revealed no significant difference, although the pooled OR numerically implicated imipenem over meropenem. The head-to-head study that compared imipenem and doripenem found a trend towards increased seizures with imipenem; however, this was a single study and this finding was not statistically significant. There were insufficient numbers to draw conclusions from the other carbapenem head-to-head analyses.
The results of our analysis lead to apparently conflicting conclusions. Imipenem was more epileptogenic than noncarbapenems, including b-lactams, whereas meropenem did not show a similar risk in a parallel comparison. However, when the two were compared head to head there was no increased epileptogenicity with imipenem. Imipenem was approved by the FDA more than a decade prior to meropenem and 33% of imipenem studies included in this analysis were conducted before the meropenem studies. The population included in the imipenem versus non-carbapenem comparator analysis is not the same as the meropenem versus non-carbapenem comparator or the imipenem versus meropenem head-to-head analyses. This is supported by the significant heterogeneity identified when summarizing effects across all carbapenems, but not when the analysis was restricted to individual carbapenems. One of the major differences identified between imipenem and meropenem studies is the use of seizure history as an exclusion criterion. In both analyses, significantly more meropenem studies and imipenem versus meropenem head-to-head studies excluded patients with a seizure history than did imipenem studies. It is also possible that, given the known seizure risk with imipenem, investigators Multiple studies included patients with more than one site of infection.
Systematic review 7 of 13 may have been biased in that they were likely not to include patients they considered to have an elevated risk of seizures, even when seizure history may not have been an exclusion criterion. This is mere speculation as it is impossible to capture that potential bias in our current analysis. It is also necessary to consider the sensitivity analysis where meningitis studies were excluded, given that meningitis is associated with seizures. 86, 87 In this analysis, the imipenem point estimate was unchanged as all three meningitis studies employed meropenem. Excluding these studies, the meropenem pooled OR increased by .2-fold. Although this finding is not statistically significant, it is a large change, suggesting that meropenem is not void of seizure risk. Therefore, based on the findings of this meta-analysis, it is unfair to characterize imipenem as more epileptogenic than Systematic review meropenem based solely on the non-carbapenem comparison when the head-to-head comparison (performed at the same time) failed to show a significant difference. That being said, in not a single analysis was meropenem associated with increased seizure risk, but, as noted above, the drugs were not exposed to the same population. The risk of carbapenem-associated seizures has been analysed in additional studies not included in our meta-analysis. No difference in CNS adverse effects between imipenem and comparator antibiotics was noted in Phase I and II studies. 2 Early imipenem studies reported an overall seizure frequency ranging from 0.9% to 3%. 89, 90 Pooled safety studies for the other carbapenems have found seizure frequencies of 0.4%, 0.2% and 0.3% among recipients of meropenem, ertapenem and doripenem, respectively. 91 -93 The present study found overall low frequencies of seizure among recipients of carbapenems, albeit higher than frequencies among recipients of non-carbapenem antibiotics.
There are some limitations of the present work that warrant discussion. The search was limited to the English language, which may have resulted in missed published data on carbapenem epileptogenicity. Many of the studies reviewed failed to provide sufficient detail regarding risk factors for seizures among patients included in the studies (e.g. CNS injury or disease, history of seizure and/or receipt of concomitant medications known to decrease the seizure threshold). In addition, due to lack of standardized reporting and inconsistent definitions, it was not always possible to assess whether seizures were likely to be drug related. Therefore, we measured all seizures that occurred during the trial regardless of whether or not they were considered to be drug related, and also conducted a sensitivity analysis of drug-related seizures. In addition, the sensitivity and subgroup analyses were not decided a priori.
Conclusions
This is the first meta-analysis to describe the comparative epileptogenicity of imipenem, meropenem, ertapenem and doripenem. The overall rate of seizures was low, but higher among recipients of carbapenems than other antibiotics. Imipenem was more epileptogenic when compared with non-carbapenem antibiotics, whereas meropenem, ertapenem and doripenem were not associated with increased seizure risk, although the drugs were studied in a different population and time period. However, based on the findings of this meta-analysis, it is unfair to characterize imipenem as more epileptogenic than meropenem based solely on the non-carbapenem comparison because the direct comparison of imipenem versus meropenem failed to yield a statistically significant difference in the frequency of epileptogenicity. 17, 20, 21, 23, 26, 29, 33 Systematic review
